Drug intelligence / Profile preview

ODP2201

Development stage: Preclinical
Lead developer: Oncocross

Overview

ODP2201 is a preclinical oncology drug candidate being developed by Oncocross. The compound was identified using the company's proprietary AI platforms, RAPTOR AI and ONCO-RAPTOR AI, which are designed to discover new indications for existing drugs or identify novel drug candidates. ODP2201 is currently in the in vitro stage of development for the treatment of oncology-related diseases. As of the current reporting, specific details regarding its biological target, molecular modality, and precise mechanism of action remain undisclosed.

Beyond the preview

Go deeper on ODP2201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ODP2201.

Explore the full profile